Neonatal Genetic Delivery of Anti-Respiratory Syncytial Virus (RSV) Antibody by Non-Human Primate-Based Adenoviral Vector to Provide Protection against RSV
Respiratory syncytial virus (RSV) is one of the leading causes of lower respiratory tract infection in infants. Immunoprophylaxis with the anti-RSV monoclonal antibody, palivizumab, reduces the risk for RSV-related hospitalizations, but its use is restricted to high-risk infants due to the high cost...
Main Authors: | Rika Gomi, Anurag Sharma, Wenzhu Wu, Stefan Worgall |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-12-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | http://www.mdpi.com/2076-393X/7/1/3 |
Similar Items
-
RSV Disease Threat and Innovative Prevention Methods in Health Protection: A Review
by: Paulina Dąbrowska, et al.
Published: (2024-02-01) -
Patient equity and respiratory syncytial virus Immunoprophylaxis
by: H. Cody Meissner
Published: (2019-01-01) -
Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
by: O'Hagan S, et al.
Published: (2023-09-01) -
Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study
by: Chiara Ratti, et al.
Published: (2023-01-01) -
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication
by: Jackelyn Murray, et al.
Published: (2022-04-01)